How does CBL-514 work? Here's the science
CBL-514 is not framed as a fat-melting or fat-burning drug. The proposed claim is that it inhibits the survival kinase DYRK1b and pushes fat cells toward apoptosis through caspase 3 and Bax/Bcl-2. That evidence comes from unpublished company reports cited in the Phase 2a and Phase 2 papers, and the chemical structure has not been disclosed. The 2025 Phase 2 trial measured ultrasound fat volume, photos, and safety, with no human biopsy or caspase data. This article separates the molecular hypothesis from what was actually measured in people, including the high dropout and single-blind design.
CBL-514 fat removal injections: What does the science say?
CBL-514 now has a placebo-controlled Phase 2 randomized trial in Aesthetic Surgery Journal, and the authors report it met its primary and secondary endpoints. But this appraisal shows why the design deserves a hard look: it was single-blind with unblinded investigators and sponsor, and the sponsor helped design, analyze and write the study. Of 75 treated participants, only 38 finished, and the per-protocol set was just 30 people. Follow-up ended 8 weeks after the final treatment, and the sample was mostly female and White. Here is what the trial can support, what it cannot, and why it is not medical advice or proof of an approved treatment.